Latest news
Loading news…
Sirion Therapeutics
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 MediumHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Tampa, Florida, United States Founded 2005 101-250 employees For Profit
Sirion Therapeutics is a biopharmaceutical company, engaged in developing, and commercializing of products for the protection of eyesight.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
1
Patents
1
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 33
- Patents granted
- 1
- Trademarks
- 0
- Top patent class
- Medical Or Veterinary Science; Hygiene
- IT spend
- $3M
Company Info
- Founded
- 2005
- Employees
- 101-250
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 2
- News articles
- 1
- HQ
- Tampa, Florida, United States
- Region
- Tampa Bay Area, East Coast, Southern US
Signals & Scores
- Heat score
- Medium
- Growth score
- Low
- Trend (7d)
- -0.1
- Trend (30d)
- 3.5
- Trend (90d)
- -0.3
Key People at Sirion Therapeutics
Co-Founder
1
professional contacts at Sirion Therapeutics
Contact execs at Sirion Therapeutics →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Sirion Therapeutics
Loading news…
FAQs about Sirion Therapeutics
People who checked this page also checked these
Browse the full Acquirezy directory.